Seattle Genetics (SGEN +4%) pops after Needham raises its price target for the shares to $25...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN +4%) pops after Needham raises its price target for the shares to $25 from $20, citing positive data presented at ASCO regarding the company's ongoing Adcetris clinical trials. Needham believes the company may succeed in adding re-treatment to the drug's label later this year, and thinks it will fill an important role in future oncology procedures.